Patel, N.
Johnson, M. A.
Vapniarsky, N.
Van Brocklin, M. W.
Williams, T. K.
Youngquist, S. T.
Ford, R.
Ewer, N.
Neff, L. P.
Hoareau, G. L.
Funding for this research was provided by:
Congressionally Directed Medical Research Programs (W81XWH-20-1-0180)
National Institutes of Health (UL1TR002538)
Article History
Received: 13 December 2022
Accepted: 10 March 2023
First Online: 18 March 2023
Competing interests
: Johnson MA, Williams TK, Neff LP: Certus Critical Care, Founders, and owners. Hoareau GL: Certus Critical Care, consultant, and shareholder. Patel N: Certus Critical Care, paid consultant, Vapniarsky N, Van Brocklin MW, Youngquist ST, Ford R, Ewer N: no conflict of interest. We do not have any conflict regarding Elamipretide.